Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Filer	Shares	Latest Filing Date	Change	Share-Type	Market Value
Jw Asset Management, Llc	1.90M	2021-02-05	1.90M	Shares	2.95M
Cowen Prime Advisors Llc	16.50K	2022-08-01	16.50K	Shares	145K
Cowen Prime Services Llc	6.30K	2021-07-16	6.30K	Shares	71K
Ubs Group Ag	916	2021-02-11	916	Shares	14K
Concourse Financial Group S...	0	2021-02-02	0	Shares	0

NASDAQ:PHAR

Pharming Group N.V.

Market Cap

572.42M

Beta: 0.95

Volume Today

1K

Avg: 26.41K

PE Ratio

−37.26

PFCF: −31.36

Institutional trades

Institutional Ownership

Current holdings institutionals